Impaired cell fate through gain-of-function mutations in a chromatin reader
- Creators
- Wan, Liling
-
Chong, Shasha
-
Xuan, Fan
- Liang, Angela
- Cui, Xiaodong
- Gates, Leah
-
Carroll, Thomas S.
-
Li, Yuanyuan
- Feng, Lijuan
-
Chen, Guochao
- Wang, Shu-Ping
-
Ortiz, Michael V.
- Daley, Sara K.
- Wang, Xiaolu
- Xuan, Hongwen
-
Kentsis, Alex
-
Muir, Tom W.
-
Roeder, Robert G.
-
Li, Haitao
- Li, Wei
-
Tjian, Robert
-
Wen, Hong
-
Allis, C. David
Abstract
Modifications of histone proteins have essential roles in normal development and human disease. Recognition of modified histones by 'reader' proteins is a key mechanism that mediates the function of histone modifications, but how the dysregulation of these readers might contribute to disease remains poorly understood. We previously identified the ENL protein as a reader of histone acetylation via its YEATS domain, linking it to the expression of cancer-driving genes in acute leukaemia. Recurrent hotspot mutations have been found in the ENL YEATS domain in Wilms tumour, the most common type of paediatric kidney cancer. Here we show, using human and mouse cells, that these mutations impair cell-fate regulation by conferring gain-of-function in chromatin recruitment and transcriptional control. ENL mutants induce gene-expression changes that favour a premalignant cell fate, and, in an assay for nephrogenesis using murine cells, result in undifferentiated structures resembling those observed in human Wilms tumour. Mechanistically, although bound to largely similar genomic loci as the wild-type protein, ENL mutants exhibit increased occupancy at a subset of targets, leading to a marked increase in the recruitment and activity of transcription elongation machinery that enforces active transcription from target loci. Furthermore, ectopically expressed ENL mutants exhibit greater self-association and form discrete and dynamic nuclear puncta that are characteristic of biomolecular hubs consisting of local high concentrations of regulatory factors. Such mutation-driven ENL self-association is functionally linked to enhanced chromatin occupancy and gene activation. Collectively, our findings show that hotspot mutations in a chromatin-reader domain drive self-reinforced recruitment, derailing normal cell-fate control during development and leading to an oncogenic outcome.
Additional Information
© The Author(s), under exclusive licence to Springer Nature Limited 2019. Received 13 December 2018. Accepted 22 October 2019. Published 18 December 2019. We thank R. Nishinakamura, A. Taguchi and Z. Li for providing reagents and discussions related to kidney differentiation assays; M. Leboeuf for technical assistance; A. Soshnev for help with figure preparation; and members of the Allis and Wen laboratories for scientific input throughout the study. We thank the Rockefeller University Genomic Resource Center, the Bio-Imaging Resource Center, the Flow Cytometry Resource Center and the MD Anderson Science Park Next-Generation Sequencing Facility (Cancer Prevention and Research Institute of Texas (CPRIT), grant RP120348). The research was supported by funds from the National Cancer Institute (grant 5R01CA204639-03), the Leukaemia and Lymphoma Society (LLS-SCOR 7006-13), and the Rockefeller University and St Jude Children's Research Hospital Collaborative on Chromatin Regulation in Pediatric Cancer (to C.D.A.); from CPRIT (grant RP160237) and the Van Andel Institute (to H.W.); and from the National Institutes of Health (NIH grants R01HG007538, R01CA193466 and R01CA228140, to W.L.). L.W. is supported by the Jane Coffin Childs Memorial Fund and an NIH Pathway to Independence Award (1K99CA226399-01). M.V.O. is supported by a K12 Award from the National Cancer Institute (K12CA184746). Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The ChIP–seq and RNA-seq data have been deposited in the Gene Expression Omnibus database under accession number GSE125186. All other raw data generated or analysed during this study are included in this paper, the Extended Data figures, and the Supplementary Information. These authors contributed equally: Shasha Chong, Fan Xuan, Angela Liang. Contributions. L.W. and H.W. conceived and designed the study. L.W., H.W., A.L. and F.X. performed most of the molecular and genomic studies. L.W. and A.L. performed kidney differentiation studies. S.C. and L.W. performed imaging studies with assistance from L.F. X.C., T.S.C., H.X. and W.L. performed bioinformatics analyses. Y.L., G.C. and H.L. performed the calorimetric studies. X.W. provided technical assistance. L.G., S.-P.W., S.K.D., R.G.R. and T.W.M. generated unpublished data. M.V.O. and A.K. provided discussion and assistance with pathology analysis. L.W. wrote the paper with critical input and edits from C.D.A., H.W., R.T., L.G., X.C., A.L. and S.C. C.D.A. and H.W. jointly supervised the research. Competing interests. C.D.A. is a co-founder of Chroma Therapeutics and Constellation Pharmaceuticals and a Scientific Advisory Board member of EpiCypher. Peer review information. Nature thanks Tanja Mittag and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.Attached Files
Accepted Version - nihms-1557361.pdf
Supplemental Material - 41586_2019_1842_Fig10_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig11_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig12_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig13_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig5_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig6_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig7_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig8_ESM.jpg
Supplemental Material - 41586_2019_1842_Fig9_ESM.jpg
Supplemental Material - 41586_2019_1842_MOESM10_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM11_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM12_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM13_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM14_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM15_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM1_ESM.pdf
Supplemental Material - 41586_2019_1842_MOESM2_ESM.pdf
Supplemental Material - 41586_2019_1842_MOESM3_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM4_ESM.mov
Supplemental Material - 41586_2019_1842_MOESM5_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM6_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM7_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM8_ESM.xlsx
Supplemental Material - 41586_2019_1842_MOESM9_ESM.xlsx
Files
Name | Size | Download all |
---|---|---|
md5:8da6b6248598b1049e1786a73854d93c
|
784.4 kB | Preview Download |
md5:21435228f50f865b9b8996ad1bdf79b9
|
1.3 MB | Download |
md5:4c610b6182fc2a86f0b83d492c27f605
|
341.9 kB | Preview Download |
md5:a5ed74ab9df297e0778224a596e03559
|
912.1 kB | Preview Download |
md5:b5f2c08d8122c21b03427b66963b5455
|
13.9 kB | Download |
md5:c2826885ea5289d1124e4f11970dee76
|
512.0 kB | Preview Download |
md5:9549033cc373de198351fcdc68739f83
|
9.3 MB | Preview Download |
md5:0a3cd18b86384adfe2f593b634dc185f
|
508.2 kB | Preview Download |
md5:20d346f8b3ce56883de9ba0e7c124468
|
12.7 kB | Download |
md5:1c758890acf096e3357300ed4d099db8
|
25.8 kB | Download |
md5:d3cc307217d9aa0c7bb7291c27df1a12
|
84.5 kB | Preview Download |
md5:e9edd107267ac8fcb76e2683c7cf241c
|
376.2 kB | Preview Download |
md5:59fe408f530095bb1d3fa5b1fad41869
|
10.4 kB | Download |
md5:b473998d5b052c505140b2fe1ca49078
|
3.5 MB | Download |
md5:e7bfcb925b836b42f3696c6bba3bf85d
|
466.1 kB | Preview Download |
md5:777c312b0d0e72f8743acdc92184d86b
|
653.7 kB | Preview Download |
md5:e3e3327c2fe01d8426d3edc6fa3fc720
|
11.7 kB | Download |
md5:95957c08e3d7615f641c987046e41c0c
|
5.7 MB | Preview Download |
md5:619d5cc7911a783ff49189e35fd7e64f
|
10.2 kB | Download |
md5:f6cf276053456a9290681fdb758ed316
|
267.9 kB | Download |
md5:ed322824d673af1fb42790b91ac32e16
|
13.5 kB | Download |
md5:f5f8e18136b2b653af7b8508d2f2a27e
|
528.4 kB | Preview Download |
md5:801b4c17980bab94a9fd10033386ad09
|
502.0 kB | Download |
md5:feae3cbe4a32c6dba9cac98c145cbd3a
|
15.8 kB | Download |
md5:c72a76a880662d443ee60b28d6a91d36
|
1.8 MB | Download |
Additional details
- PMCID
- PMC7061414
- Eprint ID
- 110713
- Resolver ID
- CaltechAUTHORS:20210902-234002184
- Cancer Prevention and Research Institute of Texas (CPRIT)
- RP120348
- NIH
- 5R01CA204639-03
- Leukaemia and Lymphoma Society
- LLS-SCOR 7006-13
- Rockefeller University
- St. Jude Children's Research Hospital
- Cancer Prevention and Research Institute of Texas (CPRIT)
- RP160237
- Van Andel Institute
- NIH
- R01HG007538
- NIH
- R01CA193466
- NIH
- R01CA228140
- Jane Coffin Childs Memorial Fund for Medical Research
- NIH
- 1K99CA226399-01
- NIH
- K12CA184746
- Created
-
2021-09-07Created from EPrint's datestamp field
- Updated
-
2021-09-07Created from EPrint's last_modified field